ALPHARETTA, Ga., July 27, 2015 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), a leading shock wave technology company, today encouraged the Company's stockholders to vote no later than tomorrow, Tuesday, July 28, 2015, their proxy on the proposal to amend the Company's Articles of Incorporation in order to increase the number of authorized shares of capital stock, par value $0.001 per share, from 155,000,000 to 355,000,000. The deadline to vote electronically, over the internet, or by phone is Tuesday, July 28, 2015 at 11:59 p.m. (Eastern Time).
A Special Meeting of stockholders of SANUWAVE will be held on Wednesday, July 29, 2015 at 9:00 a.m. (Eastern Time) at the Company's headquarters at 11475 Great Oaks Way, Alpharetta, Georgia 30022.
The foregoing item of business is more fully described in the Proxy Statement. Only stockholders of record of the Company's common stock at the close of business on June 10, 2015 will be entitled to notice of, and to vote at, the Special Meeting of stockholders or any adjournment thereof.
Your vote is important regardless of the number of shares you own. Because time is short, we encourage shareholders to vote today electronically or over the phone, per instructions on your proxy notice. If you have not received a proxy notice or have any other problems casting a vote, please contact SANUWAVE Investor Relations at 678-578-0103 for assistance.
All stockholders are cordially invited to attend the Special Meeting of stockholders in person. Only record or beneficial owners of the Company's common stock as of the record date, June 10, 2015, may vote in person at the Special Meeting. When you arrive at the Special Meeting, you must present photo identification, such as a driver's license. Beneficial owners also must provide evidence of stockholdings as of the record date, such as a recent brokerage account or bank statement.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
CONTACT: Todd Markey IR Partners 818-280-6800 email@example.com Daniel Conway DC Consulting, LLC 407-792-3333 firstname.lastname@example.org SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 617-778-9223 email@example.com